Research programme: chemokine receptor antagonists - NovartisAlternative Names: CCR5 antagonists research programme - Novartis; Chemokine receptor antagonists research programme - Novartis; NIBR 1182; NIBR 1282; Research programme: CCR5 antagonists - Novartis
Latest Information Update: 19 Jul 2010
At a glance
- Originator Novartis
- Mechanism of Action CCR5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 24 May 2004 Preclinical trials in Transplant rejection in Switzerland (unspecified route)